BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?Zacks Investment Research • 04/10/23
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health EquityBusiness Wire • 03/30/23
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New JerseyBusiness Wire • 03/21/23
Down -15.66% in 4 Weeks, Here's Why You Should You Buy the Dip in BeiGene, Ltd. (BGNE)Zacks Investment Research • 02/28/23
Here's Why BeiGene, Ltd. (BGNE) is Poised for a Turnaround After Losing -17.02% in 4 WeeksZacks Investment Research • 02/27/23
Down -14.15% in 4 Weeks, Here's Why BeiGene, Ltd. (BGNE) Looks Ripe for a TurnaroundZacks Investment Research • 02/22/23
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer CareBusiness Wire • 02/03/23
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRABusiness Wire • 01/19/23
BeiGene Announces Expansion of Coverage on China's National Reimbursement Drug ListBusiness Wire • 01/18/23
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers SymposiumBusiness Wire • 01/17/23